Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 8/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CFB | P00751 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8993312 | 0.89 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL7047687 | 0.84 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL7048861 | 0.82 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL9006740 | 0.75 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL7043892 | 0.75 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL7047719 | 0.75 | ADRA1A (0.39) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL7042987 | 0.74 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL7046794 | 0.72 | TRPV1 (0.46) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL7047731 | 0.71 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL7043711 | 0.71 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0724439-B1 | USE OF 2-(2ALKYLPHENYLAMINO)OXAZOLINES AND -THIAZOLINES FOR THE MANUFACTURE OF A MEDICAMENT WITH ALPHA 2 ADRENERGIC EFFECT | ALLERGAN SALES INC (US) | 2003-04-09 | — | — | EP | disclosed |
| US-5708015-A | SENSITIVE ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN (US) | 1998-01-13 | — | — | US | disclosed |
| US-5580892-A | ANTIDIARRHETIC, ANTISPASTIC, ANTIEPILEPTIC AGENTS; DIURETICS | ALLERGAN | 1996-12-03 | — | — | US | disclosed |
| US-5252595-A | Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines | ALLERGAN, INC. (US) | 1993-10-12 | — | — | US | disclosed |
| US-5151440-A | Treatment of glaucoma | ALLERGAN, INC. (US) | 1992-09-29 | — | — | US | disclosed |